Community-based intervention has lasting benefits, trial follow-up shows. The success of a barbershop intervention to tackle uncontrolled blood pressure (BP) among African-American men persisted at 12 months, mirroring 6-month findings of the randomized trial. Related: Uncontrolled Hypertension in African American Men: Is Cutting Blood Pressure in the Barbershop a Long-Term Solution?
The Association of Black Cardiologists collaborating with Quantum Genomics’ NEW-HOPE Study, incorporating minority inclusivity, presents Late-Breaking Trial success of novel antihypertensive agent. Firibastat meets primary endpoint and demonstrates highly significant and clinically relevant efficacy in lowering blood pressure in a diverse population whose hypertension is typically difficult to treat. These results pave the way to…
by Foluso Fakorede, MD on tackling the epidemic of PAD among minorities In 1966, Dr. Martin Luther King, Jr., observed: “Of all the forms of inequality, injustice in healthcare is the most shocking and inhumane.”
STAT (11/2, Cooney) reported that research “examining how long black or white people survive after a heart attack concludes that it’s socioeconomic status, far more than race, that explains who fares better.” The findings, authored by ABC member Dr. Garth N. Graham (et al), were published in JAMA Network Open.
Comment: “While clinicians cannot specifically control how the pharmaceutical industry sets prices for medications, we welcome any steps that increase access to agents to prevent cardiovascular events in patients with established cardiovascular disease.” Keith C. Ferdinand, MD FACC, FAHA Professor,Tulane University SOM Chair, ABC Access Initiative New Option Should Lower Out-of-Pocket Costs for America’s Seniors at…
Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices. (New York Times article, October 2, 2018)